metformin has been researched along with Thyroid Neoplasms in 34 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the role of metformin on thyroid cancer risk in patients with acromegaly." | 8.12 | Effect of metformin on thyroid cancer risk in patients with acromegaly: A preliminary observational study. ( Bektas, AB; Durcan, E; Guzel, SS; Kadioglu, P; Ozkaya, HM; Sahin, S; Sulu, C; Tay, K, 2022) |
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 7.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "Metformin is a widely used drug to treat patients with type II diabetes." | 5.43 | Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016) |
| "Metformin is a synthetic biguanide that improves insulin sensitivity and reduces hepatic gluconeogenesis." | 5.22 | Metformin in Differentiated Thyroid Cancer: Molecular Pathways and Its Clinical Implications. ( Ferreira-Hermosillo, A; García-Sáenz, M; Lobaton-Ginsberg, M, 2022) |
| "To evaluate the role of metformin on thyroid cancer risk in patients with acromegaly." | 4.12 | Effect of metformin on thyroid cancer risk in patients with acromegaly: A preliminary observational study. ( Bektas, AB; Durcan, E; Guzel, SS; Kadioglu, P; Ozkaya, HM; Sahin, S; Sulu, C; Tay, K, 2022) |
| "Sorafenib, a multikinase inhibitor has recently been approved for the treatment of radio-iodine refractory thyroid carcinoma." | 3.81 | Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. ( Chen, G; Derwahl, M; Nicula, D; Renko, K, 2015) |
| "We investigated the effect of metformin on growth of differentiated human thyroid cells, anaplastic thyroid carcinoma cells, a doxorubicin-resistant thyroid carcinoma cell line, and thyroid cancer stem cells." | 3.78 | Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. ( Chen, G; Derwahl, M; Renko, K; Xu, S, 2012) |
| "Metformin has been suggested to reduce thyroid cancer incidence and to improve thyroid cancer prognosis." | 2.82 | Metformin and thyroid carcinoma incidence and prognosis: A systematic review and meta-analysis. ( Chen, Z; Luo, J; Wang, Z; Xun, P; Zhang, Y, 2022) |
| "Anaplastic cancer constitutes 1% of thyroid cancers, and it is one of the most aggressive cancers." | 1.56 | Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells. ( Biray Avci, C; Caliskan Kurt, C; Erdogan, M; Gunduz, C; Ozdemir Kutbay, N; Sarer Yurekli, B; Shademan, B, 2020) |
| "Metformin promotes a proinflammatory phenotype by blocking anti-inflammatory cytokine response, whereas rapamycin reduces production of proinflammatory cytokines." | 1.51 | Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome. ( Hoogerbrugge, N; Netea, MG; Netea-Maier, RT; Rabold, K; Sloot, YJE; Smit, JWA, 2019) |
| "Thyroid cancer is among the most common types of malignant tumor of the endocrine system." | 1.51 | Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo. ( Chen, K; Li, R; Qi, L; Song, S; Ye, J; Zhai, W; Zhou, C, 2019) |
| "Metformin users were categorized into lowest, middle, and highest tertiles according to cumulative dose or duration of metformin therapy." | 1.48 | Protective Effect of Metformin Against Thyroid Cancer Development: A Population-Based Study in Korea. ( Cho, YY; Chung, JH; Hahm, JR; Jung, JH; Kang, MJ; Kim, SK; Kim, SW; Kim, TH; Lee, BW; Lee, YH; Nam, JY; Song, SO, 2018) |
| "Anaplastic thyroid cancer cells were treated with 0-60 mM metformin for 24, 48 and 72 h." | 1.48 | Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines. ( Azizi, F; Hedayati, M; Mohammadi-Yeganeh, S; Nozhat, Z; Zarkesh, M, 2018) |
| "131I treatment (tx) of differentiated thyroid cancer (DTC) is associated with hematopoietic toxicity." | 1.43 | Metformin Attenuates 131I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer. ( Bikas, A; Burman, KD; Desale, S; Jensen, K; Mete, M; Patel, A; Van Nostrand, D; Vasko, V; Wartofsky, L, 2016) |
| "Metformin is a widely used drug to treat patients with type II diabetes." | 1.43 | Metformin blocks progression of obesity-activated thyroid cancer in a mouse model. ( Cheng, SY; Enomoto, K; Kim, WG; Park, J; Willingham, M; Zhao, L, 2016) |
| "Metformin displays both direct and indirect anti-tumor effects." | 1.42 | Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug. ( Chiovato, L; Coperchini, F; Magri, F; Pignatti, P; Rotondi, M, 2015) |
| "Metformin inhibits thyroid cancer cell growth." | 1.42 | Glucose-deprivation increases thyroid cancer cells sensitivity to metformin. ( Bikas, A; Boyle, L; Burman, KD; Costello, J; Hoperia, V; Jensen, K; Klubo-Gwiezdzinska, J; Larin, O; McDaniel, D; Patel, A; Vasko, V; Wartofsky, L, 2015) |
| "Cases had a first-time diagnosis of thyroid cancer, six controls per case were matched on age, sex, calendar time, general practice, and number of years of active history in the database prior to the index date." | 1.42 | No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study. ( Becker, C; Bodmer, M; Jick, SS; Meier, CR, 2015) |
| "Oral metformin treatment via drinking water significantly delayed tumor growth in both tumor development model and established tumor models." | 1.40 | Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo. ( Cho, SW; Han, SK; Kim, YA; Oh, BC; Park, DJ; Park, YJ; Sun, HJ; Yi, KH, 2014) |
| "780), and all categories of the dose-response parameters showed significantly lower risk with P-trends < 0." | 1.40 | Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes. ( Tseng, CH, 2014) |
| "Treatment with metformin was associated with inhibition of mTOR/p70S6K/pS6 signaling and downregulation of pERK in both TT and MZ-CRC-1 cells." | 1.38 | Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. ( Bauer, A; Burman, KD; Costello, J; Hoperia, V; Jensen, K; Klubo-Gwiezdzinska, J; Patel, A; Vasko, V; Wartofsky, L, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 25 (73.53) | 24.3611 |
| 2020's | 9 (26.47) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 2 |
| Ogihara, T | 1 |
| Zhu, M | 1 |
| Gantumur, D | 1 |
| Li, Y | 1 |
| Mizoi, K | 1 |
| Kamioka, H | 1 |
| Tsushima, Y | 1 |
| Durai, L | 1 |
| Ravindran, S | 1 |
| Arvind, K | 1 |
| Karunagaran, D | 1 |
| Vijayalakshmi, R | 1 |
| Yu, Y | 1 |
| Feng, C | 1 |
| Kuang, J | 1 |
| Guo, L | 1 |
| Guan, H | 1 |
| García-Sáenz, M | 1 |
| Lobaton-Ginsberg, M | 1 |
| Ferreira-Hermosillo, A | 1 |
| Sulu, C | 1 |
| Bektas, AB | 1 |
| Guzel, SS | 1 |
| Tay, K | 1 |
| Sahin, S | 1 |
| Durcan, E | 1 |
| Ozkaya, HM | 1 |
| Kadioglu, P | 1 |
| Wang, Z | 1 |
| Luo, J | 1 |
| Zhang, Y | 2 |
| Xun, P | 1 |
| Chen, Z | 1 |
| Li, H | 1 |
| Chen, Y | 1 |
| Hu, L | 1 |
| Yang, W | 1 |
| Gao, Z | 1 |
| Liu, M | 1 |
| Tao, H | 1 |
| Li, J | 2 |
| Ouyang, J | 1 |
| Feng, Y | 1 |
| Liu, Y | 1 |
| Li, S | 2 |
| Wang, J | 1 |
| Tan, L | 1 |
| Zou, L | 1 |
| Ozdemir Kutbay, N | 1 |
| Biray Avci, C | 1 |
| Sarer Yurekli, B | 1 |
| Caliskan Kurt, C | 1 |
| Shademan, B | 1 |
| Gunduz, C | 1 |
| Erdogan, M | 1 |
| Kim, SH | 1 |
| Kang, JG | 1 |
| Kim, CS | 1 |
| Ihm, SH | 1 |
| Choi, MG | 1 |
| Yoo, HJ | 1 |
| Lee, SJ | 1 |
| Thakur, S | 1 |
| Daley, B | 1 |
| Gaskins, K | 1 |
| Vasko, VV | 1 |
| Boufraqech, M | 1 |
| Patel, D | 1 |
| Sourbier, C | 1 |
| Reece, J | 1 |
| Cheng, SY | 3 |
| Kebebew, E | 1 |
| Agarwal, S | 1 |
| Klubo-Gwiezdzinska, J | 4 |
| Dong, LR | 1 |
| Wang, X | 1 |
| Hu, K | 1 |
| Xiong, YJ | 1 |
| Li, M | 1 |
| Tang, H | 1 |
| Liu, AD | 1 |
| Song, XD | 1 |
| Cho, YY | 1 |
| Kang, MJ | 1 |
| Kim, SK | 1 |
| Jung, JH | 1 |
| Hahm, JR | 1 |
| Kim, TH | 1 |
| Nam, JY | 1 |
| Lee, BW | 1 |
| Lee, YH | 1 |
| Chung, JH | 1 |
| Song, SO | 1 |
| Kim, SW | 1 |
| Park, S | 1 |
| Willingham, MC | 1 |
| Qi, J | 1 |
| Noh, Y | 1 |
| Jeon, SM | 1 |
| Shin, S | 1 |
| Nozhat, Z | 1 |
| Mohammadi-Yeganeh, S | 1 |
| Azizi, F | 1 |
| Zarkesh, M | 1 |
| Hedayati, M | 1 |
| Sloot, YJE | 1 |
| Rabold, K | 1 |
| Netea, MG | 1 |
| Smit, JWA | 1 |
| Hoogerbrugge, N | 1 |
| Netea-Maier, RT | 1 |
| Ye, J | 1 |
| Qi, L | 1 |
| Chen, K | 1 |
| Li, R | 1 |
| Song, S | 1 |
| Zhou, C | 1 |
| Zhai, W | 1 |
| Schlechte, JA | 1 |
| Costello, J | 3 |
| Patel, A | 4 |
| Bauer, A | 2 |
| Jensen, K | 4 |
| Mete, M | 2 |
| Burman, KD | 4 |
| Wartofsky, L | 4 |
| Vasko, V | 4 |
| Mousavi, Z | 1 |
| Dourandish, L | 1 |
| Rokni, H | 1 |
| Sadeghi, R | 1 |
| Rasoul Zakavi, S | 1 |
| Cho, SW | 1 |
| Yi, KH | 1 |
| Han, SK | 1 |
| Sun, HJ | 1 |
| Kim, YA | 1 |
| Oh, BC | 1 |
| Park, YJ | 1 |
| Park, DJ | 1 |
| Tseng, CH | 1 |
| Rotondi, M | 1 |
| Coperchini, F | 1 |
| Pignatti, P | 1 |
| Magri, F | 1 |
| Chiovato, L | 1 |
| Chen, G | 2 |
| Nicula, D | 1 |
| Renko, K | 2 |
| Derwahl, M | 2 |
| Han, B | 1 |
| Cui, H | 1 |
| Kang, L | 1 |
| Jin, Z | 1 |
| Lu, L | 1 |
| Fan, Z | 1 |
| Kannan, S | 1 |
| Nasr, C | 1 |
| Hanly, EK | 1 |
| Bednarczyk, RB | 1 |
| Tuli, NY | 1 |
| Moscatello, AL | 1 |
| Halicka, HD | 1 |
| Geliebter, J | 1 |
| Darzynkiewicz, Z | 1 |
| Tiwari, RK | 1 |
| Bikas, A | 2 |
| McDaniel, D | 1 |
| Larin, O | 1 |
| Hoperia, V | 2 |
| Boyle, L | 1 |
| Becker, C | 1 |
| Jick, SS | 1 |
| Meier, CR | 1 |
| Bodmer, M | 1 |
| Van Nostrand, D | 1 |
| Desale, S | 1 |
| Park, J | 1 |
| Kim, WG | 1 |
| Zhao, L | 1 |
| Enomoto, K | 1 |
| Willingham, M | 1 |
| Xu, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules Size in Type 2 Diabetes: a 2-years Prospective Multicentric Study[NCT04298684] | Phase 4 | 90 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for metformin and Thyroid Neoplasms
| Article | Year |
|---|---|
Effect of metformin on
Topics: Animals; Breast Neoplasms; Carcinoma, Hepatocellular; Colonic Neoplasms; Diabetes Mellitus, Type 2; | 2022 |
Metformin in Differentiated Thyroid Cancer: Molecular Pathways and Its Clinical Implications.
Topics: Adenocarcinoma; Cell Cycle; Cell Proliferation; Diabetes Mellitus, Type 2; Humans; Insulin Resistanc | 2022 |
Metformin and thyroid carcinoma incidence and prognosis: A systematic review and meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incidence; Metformin; Thyroid Neoplasms | 2022 |
Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses.
Topics: China; Humans; Metformin; Risk; Thyroid Neoplasms | 2023 |
Should we be concerned about thyroid cancer in patients taking glucagon-like peptide 1 receptor agonists?
Topics: Animals; Blood Glucose; Contraindications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2015 |
1 trial available for metformin and Thyroid Neoplasms
| Article | Year |
|---|---|
Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Body Weight; Carcinoma, Papillary; Dose-Response Relationship, Dr | 2014 |
28 other studies available for metformin and Thyroid Neoplasms
| Article | Year |
|---|---|
Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Humans; Metformin; | 2021 |
Metformin exerts an antitumoral effect on papillary thyroid cancer cells through altered cell energy metabolism and sensitized by BACH1 depletion.
Topics: Animals; Basic-Leucine Zipper Transcription Factors; Cell Line, Tumor; Cell Movement; Cell Prolifera | 2022 |
Effect of metformin on thyroid cancer risk in patients with acromegaly: A preliminary observational study.
Topics: Acromegaly; Adult; Case-Control Studies; Humans; Insulin-Like Growth Factor I; Metformin; Thyroid Ne | 2022 |
Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication.
Topics: Cell Line, Tumor; Cell Proliferation; DNA Replication; Gene Expression Profiling; Glycolysis; Humans | 2023 |
Effects of metformin and pioglitazone combination on apoptosis and AMPK/mTOR signaling pathway in human anaplastic thyroid cancer cells.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Drug Therapy, Combination; Gene Expressi | 2020 |
Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.
Topics: AMP-Activated Protein Kinases; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell | 2018 |
Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Glycerolphosphate Dehydrogenase; Glycolysis; Heterogr | 2018 |
[Effects of metformin on papillary thyroid carcinoma in nude rats model].
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferatio | 2018 |
Protective Effect of Metformin Against Thyroid Cancer Development: A Population-Based Study in Korea.
Topics: Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypog | 2018 |
Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer.
Topics: Animals; Antineoplastic Agents; Azepines; Cell Proliferation; Diet, High-Fat; Disease Models, Animal | 2018 |
Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Dipeptidyl-P | 2019 |
Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug | 2018 |
Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome.
Topics: Adult; beta-Glucans; Case-Control Studies; Cell Line, Tumor; Coculture Techniques; Cytokines; Germ-L | 2019 |
Metformin induces TPC-1 cell apoptosis through endoplasmic reticulum stress-associated pathways in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum Chaperone BiP; Endop | 2019 |
Update in endocrinology: evidence published in 2012.
Topics: Biliopancreatic Diversion; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; | 2013 |
Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer.
Topics: Adult; Aged; Cell Movement; Cell Proliferation; Diabetes Mellitus; Disease-Free Survival; Female; Hu | 2013 |
Therapeutic potential of metformin in papillary thyroid cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cells | 2014 |
Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Databases, Factual; Diabetes Mellitus, Type 2; Female; | 2014 |
Metformin reverts the secretion of CXCL8 induced by TNF-α in primary cultures of human thyroid cells: an additional indirect anti-tumor effect of the drug.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Cell Death; Cell Proliferation; Cells, Cultu | 2015 |
Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response | 2015 |
Metformin inhibits thyroid cancer cell growth, migration, and EMT through the mTOR pathway.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Gen | 2015 |
mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.
Topics: Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Res | 2015 |
Glucose-deprivation increases thyroid cancer cells sensitivity to metformin.
Topics: Adenocarcinoma, Follicular; AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Papillary; Carrier | 2015 |
No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Female; Humans; Hypoglycemi | 2015 |
Metformin Attenuates 131I-Induced Decrease in Peripheral Blood Cells in Patients with Differentiated Thyroid Cancer.
Topics: Adult; Aged; Blood Platelets; Bone Marrow Cells; Erythrocyte Count; Female; Hemoglobins; Humans; Hyp | 2016 |
Metformin blocks progression of obesity-activated thyroid cancer in a mouse model.
Topics: Adenocarcinoma, Follicular; Anaplasia; Animals; Antineoplastic Agents; Cell Proliferation; Diet, Hig | 2016 |
Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
Topics: Adenocarcinoma, Follicular; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell D | 2012 |
Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.
Topics: AMP-Activated Protein Kinase Kinases; Anoikis; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cel | 2012 |